Zimbabwe has declined a major American healthcare agreement valued at $367m (272 million pounds) over five years due to the United States' request for sensitive information.
The decision became public after a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson later explained that the US was seeking genetic material for scientific study and commercial gain while was unwilling to guarantee the benefits from any future vaccines.
"We are forced to start the challenging and unfortunate process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn as health assistance to Zimbabwe over the last twenty years.
A physicians' group in Zimbabwe has appealed for continued negotiations to find a deal agreeable to both sides so the country's vital HIV programme can be sustained.
Wider Context
This rejection comes after a similar situation in Kenya, where a high court suspended a similar health funding agreement after legal challenges were filed about the security of Kenyans' medical information.
After returning to the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was pursuing direct bilateral deals to enhance transparency and accountability.
As per reports, 16 African countries have so far signed these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Declined Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded initiatives," the Ambassador added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, with no equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that provided information," his statement read.
"In essence, our country would supply the raw materials for medical research without any assurance that the end products would be available to our population should a new health crisis arise."
Sovereignty and Global Health
Mangwana further noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures already set up through the global organization.
The spokesperson gave as an example its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This mechanism is intended to guarantee that when a nation contributes its data, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how future collaboration could be arranged in a way that honours the independence and dignity of both nations."
Medical Community Reaction
Medical experts said it understood the government's concerns, but urged that talks must proceed considering a large portion of the country's Aids initiatives depended on foreign aid.
"In cases where specific concerns exist, including those relating to information security or implementation frameworks, these can frequently be addressed via technical clarification and mutually agreed protections," the group added.
The situation underscores the continuing debate between accepting much-needed international aid and protecting local interests in an increasingly data-driven world.